|

The U.S. Food and Drug Administration today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world. The GRDP marks a major step forward in the FDA's global leadership and may accelerate patient access to innovative therapies throughout the world.
The GRDP enables the FDA to more efficiently share minimally redacted approval packages, including the FDA's detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside of the United States, empowering those authorities to rely on the FDA's rigorous, science-based review decisions rather than conducting duplicative and time-consuming product evaluations of their own, while maintaining sovereignty over their regulatory decision.
"The GRDP is a prime example of America First policies improving public health worldwide," said Grace Graham, FDA Deputy Commissioner for Policy, Legislation, and International Affairs. "The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America’s continued interest in advancing global health under the Trump Administration."
|
|
|
|